See more : Nabtesco Corporation (NCTKY) Income Statement Analysis – Financial Results
Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Samick THK Co., Ltd. (004380.KS) Income Statement Analysis – Financial Results
- Pacific Smiles Group Limited (PSQ.AX) Income Statement Analysis – Financial Results
- Tokyo Board Industries Co., Ltd. (7815.T) Income Statement Analysis – Financial Results
- ZYF Lopsking Aluminum Co., Ltd. (002333.SZ) Income Statement Analysis – Financial Results
- Pathfinder Ventures Inc. (RVRVF) Income Statement Analysis – Financial Results
Compugen Ltd. (CGEN)
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.46M | 7.50M | 6.00M | 2.00M | 0.00 | 17.80M | 0.00 | 712.00K | 9.28M | 12.37M | 3.55M | 242.00K | -424.00K | 1.12M | 250.00K | 338.00K | 180.00K | 215.00K | 646.00K | 4.03M | 8.83M | 11.10M | 11.36M | 6.89M | 3.24M |
| Cost of Revenue | 2.00M | 975.00K | 680.00K | 60.00K | 989.00K | 1.03M | 1.59M | 223.00K | 1.63M | 3.34M | 2.51M | 201.00K | 424.00K | 224.00K | 0.00 | 7.00K | 0.00 | 6.00K | 148.00K | 1.10M | 2.28M | 2.82M | 3.46M | 478.00K | -769.00K |
| Gross Profit | 31.46M | 6.53M | 5.32M | 1.94M | -989.00K | 16.77M | -1.59M | 489.00K | 7.64M | 9.02M | 1.04M | 41.00K | -848.00K | 891.00K | 250.00K | 331.00K | 180.00K | 209.00K | 498.00K | 2.93M | 6.55M | 8.28M | 7.91M | 6.41M | 4.01M |
| Gross Profit Ratio | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | 200.00% | 79.91% | 100.00% | 97.93% | 100.00% | 97.21% | 77.09% | 72.68% | 74.22% | 74.60% | 69.59% | 93.06% | 123.76% |
| Research & Development | 34.47M | 30.65M | 28.69M | 22.76M | 19.82M | 30.32M | 28.58M | 24.55M | 21.25M | 15.07M | 12.28M | 9.44M | 6.78M | 5.23M | 5.05M | 8.75M | 8.39M | 9.81M | 10.47M | 12.32M | 13.31M | 14.17M | 15.98M | 12.17M | 6.68M |
| General & Administrative | 9.73M | 10.32M | 10.86M | 9.81M | 8.41M | 8.04M | 7.63M | 7.35M | 6.01M | 5.45M | 4.85M | 3.46M | 4.59M | 2.91M | 2.15M | 3.50M | 0.00 | 0.00 | 0.00 | 3.61M | 4.38M | 5.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 244.00K | 932.00K | 842.00K | 871.00K | 651.00K | 1.63M | 1.19M | 1.17M | 1.31M | 838.00K | 962.00K | 684.00K | 610.00K | 633.00K | 681.00K | 996.00K | 0.00 | 0.00 | 0.00 | 5.54M | 6.57M | 3.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.98M | 11.25M | 11.70M | 10.68M | 9.06M | 9.68M | 8.82M | 8.52M | 7.32M | 6.29M | 5.81M | 4.14M | 5.20M | 3.54M | 2.83M | 4.50M | 4.25M | 4.39M | 4.91M | 6.19M | 7.46M | 9.15M | 10.95M | 9.18M | 4.32M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -523.00K | -811.00K | -588.00K | 281.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.82M | 18.44M | 13.89M | 0.00 | 0.00 | 1.86M |
| Operating Expenses | 44.45M | 41.90M | 40.39M | 33.44M | 28.88M | 39.99M | 37.41M | 33.07M | 28.56M | 21.36M | 18.08M | 13.58M | 11.98M | 8.77M | 7.88M | 13.24M | 12.64M | 14.20M | 15.38M | 18.50M | 20.77M | 23.32M | 26.92M | 21.35M | 12.85M |
| Cost & Expenses | 46.45M | 42.87M | 41.07M | 33.50M | 28.88M | 41.03M | 37.41M | 33.30M | 30.20M | 24.70M | 20.59M | 13.78M | 11.98M | 8.99M | 7.88M | 13.25M | 12.64M | 14.21M | 15.52M | 19.60M | 23.04M | 26.14M | 30.38M | 21.83M | 12.09M |
| Interest Income | 3.24M | 1.74M | 894.00K | 1.77M | 935.00K | 643.00K | 523.00K | 728.00K | 815.00K | 346.00K | 169.00K | 301.00K | 0.00 | 0.00 | 0.00 | 502.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 31.00K | 27.00K | 25.00K | 42.00K | 32.00K | 620.00K | 508.00K | 705.00K | 755.00K | 330.00K | 141.00K | 240.00K | -306.00K | 241.00K | 65.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 476.00K | 482.00K | 461.00K | 715.00K | 989.00K | 1.39M | 1.59M | 1.48M | 1.11M | 658.00K | 370.00K | 299.00K | 179.00K | 201.00K | 264.00K | 477.00K | 633.00K | 996.00K | 2.39M | 1.76M | 2.68M | 2.90M | 4.28M | 4.99M | 1.86M |
| EBITDA | -12.52M | -35.37M | -34.61M | -31.50M | -27.04M | -21.83M | -35.46M | -31.10M | -19.81M | -12.34M | -17.04M | -13.27M | -11.81M | -7.68M | -7.37M | -12.03M | -11.83M | -13.08M | -12.49M | -13.81M | -12.20M | -12.15M | -14.74M | -9.94M | -6.99M |
| EBITDA Ratio | -37.41% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,891.51% | -767.09% | -4,566.00% | -3,835.80% | -6,578.33% | -6,095.81% | -1,967.49% | -353.89% | -138.26% | -109.45% | -126.73% | -145.13% | -215.32% |
| Operating Income | -12.99M | -35.37M | -35.07M | -31.50M | -28.88M | -23.23M | -37.41M | -32.58M | -20.92M | -12.34M | -17.04M | -13.54M | -11.98M | -7.88M | -7.63M | -12.91M | -12.46M | -13.99M | -14.88M | -15.58M | -14.22M | -15.04M | -19.02M | -16.18M | -8.85M |
| Operating Income Ratio | -38.83% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,825.24% | -706.55% | -3,051.60% | -3,820.12% | -6,922.22% | -6,508.37% | -2,303.10% | -386.81% | -161.07% | -135.57% | -167.42% | -234.74% | -273.34% |
| Total Other Income/Expenses | 3.21M | 1.74M | 871.00K | 1.80M | 820.00K | 628.00K | 339.00K | 1.10M | 1.15M | 1.76M | 3.46M | -86.00K | 0.00 | 675.00K | 3.79M | 401.00K | 1.00M | 1.94M | 900.00K | 1.86M | 2.77M | 2.84M | -348.00K | 1.30M | -18.00K |
| Income Before Tax | -9.78M | -33.64M | -34.20M | -29.70M | -28.06M | -22.60M | -37.07M | -31.49M | -19.77M | -10.73M | -13.58M | -13.63M | -12.00M | -7.44M | -3.84M | -12.51M | -11.46M | -13.88M | -14.66M | -15.14M | -13.55M | -13.40M | -19.37M | -14.87M | -8.87M |
| Income Before Tax Ratio | -29.24% | -448.48% | -570.05% | -1,484.90% | 0.00% | -126.96% | 0.00% | -4,422.19% | -213.14% | -86.80% | -382.73% | -5,631.40% | 2,831.13% | -667.62% | -1,537.20% | -3,701.48% | -6,365.56% | -6,457.67% | -2,269.35% | -375.94% | -153.57% | -120.79% | -170.48% | -215.85% | -273.90% |
| Income Tax Expense | 8.97M | 58.00K | -1.33M | -2.44M | -722.00K | -1.26M | -678.00K | 20.00K | 390.00K | 360.00K | 500.00K | -416.00K | 331.00K | -1.35M | -7.58M | -37.00K | 32.00K | -1.08M | -1.12M | -2.29M | -3.44M | -2.84M | -3.53M | -1.59M | -701.00K |
| Net Income | -18.75M | -33.69M | -32.87M | -27.26M | -27.34M | -22.60M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12.00M | -7.20M | -3.83M | -12.53M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.20M | -15.14M | -13.40M | -8.13M |
| Net Income Ratio | -56.05% | -449.25% | -547.88% | -1,363.00% | 0.00% | -126.96% | 0.00% | -4,425.00% | -217.34% | -89.71% | -396.82% | -5,631.40% | 2,831.13% | -646.01% | -1,532.40% | -3,706.21% | -6,730.00% | -6,055.81% | -2,163.78% | -340.75% | -129.64% | -109.98% | -133.31% | -194.51% | -251.13% |
| EPS | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| EPS Diluted | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| Weighted Avg Shares Out | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 47.81M | 38.87M | 35.84M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
| Weighted Avg Shares Out (Dil) | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca...
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on January 4, 2024, it received a notification letter (the "Notification Letter")...
Gilead Sciences and Compugen strike commercialization deal for immunotherapy program
Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has entered into an agreement with Compugen Ltd (NASDAQ:CGEN) to exclusively license Compugen's pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate, which is targeting cancer. Per the agreement, Compugen will...
Why Are Stocks Up Today?
Stocks are up today and investors wondering why will want to keep reading as we have a breakdown of the market's rally on Tuesday! The big catalyst keeping stocks up today comes from high investor hopes for interest rate cuts...
Why Is Compugen (CGEN) Stock Up 189% Today?
Compugen (NASDAQ: CGEN ) stock is rocketing higher on Tuesday after announcing an exclusive licensing agreement with Gilead Sciences (NASDAQ: GILD ). According to a press release from Compugen, this agreement covers its anti-IL-18 binding protein program.
Compugen stock rockets on anti-tumor drug deal with Gilead
Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage development and commercialization of Anti-IL 18 binding...
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a...
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery,...
7 Promising Penny Stocks With the Potential to Defy Expectations
You know you want it. High-potential penny stocks that is.
Source: https://incomestatements.info
Category: Stock Reports